Systematic review of blinding assessment in randomized controlled trials in schizophrenia and affective disorders 2000-2010

Psychotherapy and Psychosomatics

Volumn 82, Issue 3, 2013, Pages 152-160

  Baethge, Christopher ^a   Assall, Oliver P ^a   Baldessarini, Ross J ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Blinding assessment; Controlled trials; Mood disorders; Quality of reports; Schizophrenia; Therapeutics

Indexed keywords

BRAIN DEPTH STIMULATION; CLINICAL ASSESSMENT; CONTINGENCY TABLE; DEPRESSION; EFFECT SIZE; FORCED CHOICE METHOD; HUMAN; INTENTION TO TREAT ANALYSIS; MEDICAL DOCUMENTATION; MOOD DISORDER; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; ARTICLE; BLINDING METHOD; DOCUMENTATION; METHODOLOGY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS;

BIAS (EPIDEMIOLOGY); DOUBLE-BLIND METHOD; HUMANS; MOOD DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); PUBLISHING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH REPORT; SCHIZOPHRENIA; SINGLE-BLIND METHOD;

EID: 84875651886     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000346144     Document Type: Review

References (35)

1. Schulz KF, Chalmers I, Hayes R.J., Altmann DG: Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273:408-412.
2. Jüni P., Altman DG, Egger M: Assessing the quality of controlled clinical trials. BMJ 2001; 323:42-46.
3. Wood L, Egger M, Gluud L.L., Schulz KF, Jüni P, Altman D.G., Gluud C., Martin RM, Wood AJ, Sterne JA: Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008; 336: 601-605. (Pubitemid 351439518)
4. Perlis RH, Ostacher M, Fava M., Nierenberg AA, Sachs GS, Rosenbaum JF: Assuring that double-blind is blind. Am J Psychiatry 2010; 167:250-252.
5. Kelley JM, Kaptchuk TJ, Cusin C, Lipkin S., Fava M: Open-label placebo for major depressive disorder: a pilot randomized controlled trial. Psychother Psychosom 2012; 81:312-314.
6. Merlo-Pich E., Alexander RC, Fava M, Gome-ni R: A new population-enrichment strategy to improve efficiency of placebo-controlled clinical trials of antidepressant drugs. Clin Pharmacol Ther 2010; 88:634-642.
7. Papakostas GI, Fava M: Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neu-ropsychopharmacol 2009; 19:34-40.
8. Başoǧlu M, Marks I, Livnou M, Swinson R: Double-blindness procedures, rater blindness, and ratings of outcome: observations from a controlled trial. Arch Gen Psychiatry 1997; 54:744-748. (Pubitemid 27344102)
9. Boutron I, Estellat C, Ravaud P: Review of blinding in randomized controlled trials found results inconsistent and questionable. J Clin Epidemiol 2005; 58:1220-1226. (Pubitemid 41608537)
10. Hróbjartsson A., Forfang E, Haahr M.T., Als-Nielsen B, Brorson S: Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding. Int J Epidemiol 2007; 36:654-663. (Pubitemid 47244571)
11. Rickels K, Lipman RS, Fisher S, Park L.C., Uhlenhuth EH: Is a double-blind clinical trial really double-blind? Report of doctors' medication guesses. Psychopharmacologia 1970; 16:329-336.
12. Kleber HD, Weissman MM, Rounsaville B.J., Wilber CH, Prusoff BA, Riordan CE: Imipra-mine as treatment for depression in addicts. Arch Gen Psychiatry 1983; 40:649-653.
13. Ney PG, Collins C, Spensor C: Double blind: double talk, or are there ways to do better research? Med Hypotheses 1986; 21:119-126. (Pubitemid 17201922)
14. Oxtoby A, Jones A, Robinson M: Is your 'double-blind' design truly double-blind? Br J Psychiatry 1989; 155:700-701.
15. Fisher S, Greenberg RP: How sound is the double-blind design for evaluating psycho-tropic drugs? J Nerv Ment Dis 1993; 181:345-350. (Pubitemid 24259604)
16. Sackeim HA, Haskett RF, Mulsant B.H., Thase ME, Mann JJ, Pettinati HM, Greenberg R.M., Crowe RR, Cooper TB, Prudic J: Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: randomized controlled trial. JAMA 2001; 285: 1299-1307. (Pubitemid 32216144)
17. Fergusson D, Cranley Glass K, Waring D, Shapiro S: Turning a blind eye: the success of blinding reported in a random sample of randomized, placebo controlled trials. BMJ 2004; 328:432.
18. Ghaemi SN: Clinician's Guide to Statistics and Mental Health. Cambridge, Cambridge University Press, 2009, pp 19-20.
19. Fitzgerald PB, Benitez J, de Castella A, Daska-lakis ZJ, Brown T.L., Kulkarni J: A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. Am J Psychiatry 2006; 163:88-94. (Pubitemid 43050108)
20. James EK, Bloch DA, Lee K.K., Kraemer HC, Fuller RK: An index for assessing blindness in a multi-center clinical trial of disulfiram for alcohol cessation: a VA cooperative study. Stat Med 1996; 15:1421-1434. (Pubitemid 26242551)
21. Bang H, Ni L, Davis CE: Assessment of blinding in clinical trials. Control Clin Trials 2003; 25:143-156. (Pubitemid 38328755)
22. Altman DG, Schulz KF, Moher D, Egger M., Davidoff F, Elbourne D, Gotzsche P.C., Lang T., CONSORT GROUP (Consolidated Standards of Reporting Trials): The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134:663-694. (Pubitemid 32322245)
23. Colagiuri B, Boakes RA: Perceived treatment, feedback, and placebo effects in double-blind RCTs: an experimental analysis. Psychophar-macology 2010; 208:433-441.
24. Rief W, Bingel U, Schedlowski M., Enck P: Mechanisms involved in placebo and nocebo responses and implications for drug trials. Clin Pharmacol Ther 2011; 90:722-726.
25. Sackett DL: Measuring the success of blinding RCTs: don't, must, can't, or needn't? Int J Epidemiol 2007; 36:664-665. (Pubitemid 47244572)
26. Schulz KF, Altmann DG, Moher D: CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010; 152:726-732.
27. Crumley ET, Wiebe N, Cramer K., Klassen TP, Hartling L: Which resources should be used to identify RCT/CCTs for systematic reviews: systematic review. BMC Med Res Methodol 2005; 5:24.
28. Galandi D, Schwarzer G, Antes G: Demise of the randomized controlled trial: bibliometric study of the German-language healthcare literature, 1948 to 2004. BMC Med Res Meth-odol 2006; 6:30.
29. Baethge C: The languages of medicine. Dtsch Arztebl Int 2008; 105:37-40. (Pubitemid 351373384)
30. Heidenreich U, Baethge C: German language psychiatry journals in Germany: a quantitative analysis. Psychiatr Prax 2012; 39:26-33.
31. Kolahi J, Bang H, Park J: Towards a proposal for assessment of blinding success in clinical trials. Commun Dent Oral Epidemiol 2009; 37:477-484.
32. Hróbjartsson A., Boutron I: Blinding in randomized clinical trials: imposed impartiality. Clin Pharmacol Ther 2011; 90:732-736.
33. Sharpe L, Ryan B, Allard S., Sansky T: Testing for the integrity of blinding in clinical trials: how valid are forced choice paradigms? Psy-chother Psychosom 2003; 72:128-131. (Pubitemid 36469861)
34. Hopton AK, MacPherson H: Assessing blinding in randomised controlled trials of acupuncture: challenges and recommendations. Chin J Integr Med 2011; 17:173-176.
35. Bang H, Flaherty SP, Kolahi J, Park J: Blinding assessment in clinical trials: a review of statistical methods and a proposal of blinding assessment protocol. Clin Res Regul Aff 2010; 27:42-51.